A growing focus of established market players such as Becton, Dickinson & Company and Cook Medical Inc. towards developing biocompatible and biodegradable materials for stents used in stricture treatments can be observed in the global market. The emergence and acceptance of biodegradable stents present a promising substitute for conventional stents, as they gradually degrade and are absorbed by the body, potentially lowering the chances of enduring complications in the long term.
Authors:
Mariam Faizullabhoy, Gauri Wani
Frequently Asked Questions (FAQ) :
Endoscopic stricture management device market was valued at USD 881 million in 2023 and is set to reach USD 1.4 billion by 2032, driven by growing occurrence of conditions that result in strictures, such as gastroesophageal reflux.
The esophageal application segment held the 36.6% of the endoscopic stricture management device industry share in 2023 and is set to grow rapidly by 2032, owing to high incidence of strictures caused in esophageal region.
North America endoscopic stricture management device market held a robust share in 2023 and is set to reach USD 543.6 million by 2032, owing to rising incidence of diseases such as GERD.
Boston Scientific Corporation, Olympus Corporation, CONMED Corporation, Cook Medical Inc., Becton, Dickinson and Company, Merit Medical Systems, Medi-Globe GmbH, PanMed Us, HOBBS MEDICAL, INC., Micro-Tech (Nanjing) Co., Ltd among others.